Meet FutureMeds at SCRS Global Booth #619

As a dedicated and fully owned site network with a DCT service provider operating across Europe, we’re happy to discuss how our model is impacting recruitment, geographic reach, and quality outcomes for sponsors and CROs. Visit us at Booth #619 to learn more. 

FutureMeds representatives are excited to join the upcoming Global Site Solutions Summit in Orlando. SCRS Global is a cornerstone event in our clinical research calendar, offering a unique opportunity for exploring potential collaborations with sponsors, CROs and solution providers and comparing notes with sites.  

“Sponsors and CROs are looking for site and DCT partners they can count on. Partners who deliver consistency, offer scalability, and maintain a strong focus on patients. At FutureMeds, we’re proud of the momentum we’ve built across Europe, and our team looks forward to sharing our insights and experiences at SCRS Global.”   

— Dr Radoslaw Janiak, Chief Executive Officer  

Recent Milestones Highlighting FutureMeds' Progress 

Since starting our first trial in 2020, we’ve achieved several key milestones that reflect the progress our teams have achieved and the value we have provided for our clients.

Some of the key milestones: 

• Strategic Partnership with Phoenix

  We’re scaling our site network and access across Europe and beyond, backed by long-term investment and shared strategic vision.  
  

• Medpace Flagship Site Network Status  FutureMeds became the first private site network selected by Medpace for its Flagship Programme as a recognition of our speed, quality, and collaborative site model. 

• IQVIA Prime Site Network Partner 

  The IQVIA Prime Site program provides long-term strategic collaboration with sites characterised by clinical and technological excellence and we are a proud member of their program.   

  
  

• FutureMeds @home   Our decentralised trial solution, FutureMeds @home expanded startup capabilities across Europe. Throughout the 13+ year history of the service, FutureMeds @home supported over 320 DCT Phase I-IV studies across 120+ indications, recruited 28k+ patients and delivered 14,500+ Homecare visits  

• Community-Based Patient Engagement   Our teams at FutuerMeds developed a community-based, patient-centric model for oncology trials, blending the reliability of dedicated research sites with the flexibility of decentralised elements.  
  

• Robust Quality and Regulatory Oversight  Our Quality Management System continues to deliver confidence at scale. This year alone FutureMeds underwent 4 FDA Inspections (No 483 Form), 1 Client System Audit (No Critical Finding), 1 Regulatory Inspection (report pending), 9 Sponsor Audits - (No Critical findings), 2 DCT - Sub-contractor qualification audit (No Critical Finding) 

Meet the Team at Booth #619 

Our team attending SCRS Global will include: 

• This year, the following team members will represent FutureMeds: 

• Radoslaw (Radek) Janiak, Chief Executive Officer 

• Cameron Glen, VP, Global Business Development 

• Nachiket Chandak, Senior Director, Business Development 

• Ninon Armbrust, Managing Director, FutureMeds Germany 

• Jakub J., Global Project Manager 
  

Our team looks forward to exchanging perspectives on the current challenges and opportunities facing global trial delivery. 

“We’re excited to meet and welcome conversations with sponsors and CROs who are looking for practical insights from sites and a DCT service that operate day-to-day across multiple trial types and geographies across Europe.”  

— Cameron Grieve, VP, Global Business Development 

If you’re a U.S.-based sponsor or CRO planning trials in Europe, stop by Booth #619 to meet the team behind one of the fastest-growing dedicated site networks in Europe.